265. Lipodystrophy Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 112 / Drugs : 155 - (DrugBank : 55) / Drug target genes : 25 - Drug target pathways : 97
Lipodystrophy and other diseases between which drug repositioning might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Drug repositionability
| ID | Diseases (Sorted by drug repositionability) |
|---|---|
| 265 | Lipodystrophy |
| 46 | Malignant rheumatoid arthritis |
| 96 | Crohn disease |
| 299 | Cystic fibrosis |
| 97 | Ulcerative colitis |
| 13 | Multiple sclerosis/Neuromyelitis optica |
| 78 | Hypopituitarism |
| 2 | Amyotrophic lateral sclerosis |
| 6 | Parkinson disease |
| 236 | Pseudohypoparathyroidism |
| 63 | Idiopathic thrombocytopenic purpura |
| 21 | Mitochondrial disease |
| 246 | Methylmalonic acidemia |
| 65 | Primary immunodeficiency |
| 226 | Interstitial cystitis with Hunners ulcer |
| 84 | Sarcoidosis |
| 49 | Systemic lupus erythematosus |
| 8 | Huntington disease |
| 162 | Pemphigoid |
| 51 | Scleroderma |
| 271 | Ankylosing spondylitis |
| 50 | Dermatomyositis |
| 107 | Juvenile idiopathic arthritis |
| 93 | Primary biliary cholangitis |
| 77 | Growth hormone secreting pituitary adenoma |
| 268 | Nakajo-Nishimura syndrome |
| 325 | Hereditary autoinflammatory syndrome |
| 195 | Noonan syndrome |
| 263 | Cerebrotendinous xanthomatosis |
| 294 | Congenital diaphragmatic hernia |
| 81 | Congenital adrenal hyperplasia |
| 86 | Pulmonary arterial hypertension |
| 56 | Behcet disease |
| 67 | Polycystic kidney disease |
| 310 | Congenital anomalies syndrome |
| 94 | Primary sclerosing cholangitis |
| 113 | Muscular dystrophy |
| 75 | Cushing disease |
| 301 | Macular dystrophy |
| 225 | Congenital nephrogenic diabetes insipidus |
| 232 | Carney complex |
| 324 | Methylglutaconic aciduria |
| 191 | Werner syndrome |